Compare SPCB & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPCB | CUE |
|---|---|---|
| Founded | 1988 | 2014 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.3M | 49.6M |
| IPO Year | N/A | 2018 |
| Metric | SPCB | CUE |
|---|---|---|
| Price | $8.48 | $0.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $18.00 | $3.00 |
| AVG Volume (30 Days) | 50.7K | ★ 1.7M |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | ★ $26,739,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.13 | $25.00 |
| P/E Ratio | $10.34 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.06 | $0.23 |
| 52 Week High | $18.95 | $1.75 |
| Indicator | SPCB | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 39.26 | 46.43 |
| Support Level | $8.98 | $0.23 |
| Resistance Level | $9.47 | $0.44 |
| Average True Range (ATR) | 0.49 | 0.05 |
| MACD | -0.08 | 0.02 |
| Stochastic Oscillator | 11.11 | 74.50 |
SuperCom Ltd is an Israel-based provider of traditional and digital identity solutions, providing safety, identification, tracking, and security products to governments and organizations. The company comprises three main Strategic Business Units: e-Gov; IoT, which is the key revenue driver; and Cyber Security. The Company's IoT products and solutions reliably identify, track and monitor people or objects in real time, enabling the customers to detect unauthorized movement of people, vehicles and other monitored objects. The geographical segments of the company include Africa, European countries, South America, the United States, Israel, and APAC.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.